GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sonoma Pharmaceuticals Inc (NAS:SNOA) » Definitions » E10

Sonoma Pharmaceuticals (Sonoma Pharmaceuticals) E10 : $-6.55 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Sonoma Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Sonoma Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was $-0.080. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-6.55 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average E10 Growth Rate was 34.40% per year. During the past 5 years, the average E10 Growth Rate was 33.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Sonoma Pharmaceuticals was 44.70% per year. The lowest was 30.00% per year. And the median was 37.30% per year.

As of today (2024-05-11), Sonoma Pharmaceuticals's current stock price is $0.1455. Sonoma Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 was $-6.55. Sonoma Pharmaceuticals's Shiller PE Ratio of today is .


Sonoma Pharmaceuticals E10 Historical Data

The historical data trend for Sonoma Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonoma Pharmaceuticals E10 Chart

Sonoma Pharmaceuticals Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -47.11 -34.13 -24.20 -16.19 -9.63

Sonoma Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.96 -9.63 -8.23 -7.09 -6.55

Competitive Comparison of Sonoma Pharmaceuticals's E10

For the Drug Manufacturers - Specialty & Generic subindustry, Sonoma Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sonoma Pharmaceuticals's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sonoma Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Sonoma Pharmaceuticals's Shiller PE Ratio falls into.



Sonoma Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sonoma Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.08/129.4194*129.4194
=-0.080

Current CPI (Dec. 2023) = 129.4194.

Sonoma Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201403 44.550 99.695 57.833
201406 -0.450 100.560 -0.579
201409 -3.600 100.428 -4.639
201412 -31.050 99.070 -40.562
201503 -4.950 99.621 -6.431
201506 -6.930 100.684 -8.908
201509 -4.860 100.392 -6.265
201512 -8.640 99.792 -11.205
201603 -7.200 100.470 -9.275
201606 -5.490 101.688 -6.987
201609 -4.140 101.861 -5.260
201612 34.560 101.863 43.909
201703 -5.190 102.862 -6.530
201706 -7.380 103.349 -9.242
201709 -6.030 104.136 -7.494
201712 -6.570 104.011 -8.175
201803 -8.370 105.290 -10.288
201806 -4.990 106.317 -6.074
201809 -3.930 106.507 -4.775
201812 -2.370 105.998 -2.894
201903 -1.980 107.251 -2.389
201906 0.540 108.070 0.647
201909 -0.920 108.329 -1.099
201912 -0.720 108.420 -0.859
202003 -1.100 108.902 -1.307
202006 0.130 108.767 0.155
202009 0.060 109.815 0.071
202012 -0.320 109.897 -0.377
202103 -1.820 111.754 -2.108
202106 -0.520 114.631 -0.587
202109 -0.040 115.734 -0.045
202112 -0.310 117.630 -0.341
202203 -1.070 121.301 -1.142
202206 -0.290 125.017 -0.300
202209 -0.330 125.227 -0.341
202212 -0.620 125.222 -0.641
202303 -0.280 127.348 -0.285
202306 -0.290 128.729 -0.292
202309 -0.290 129.860 -0.289
202312 -0.080 129.419 -0.080

Add all the adjusted EPS together and divide 10 will get our e10.


Sonoma Pharmaceuticals  (NAS:SNOA) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Sonoma Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Sonoma Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Sonoma Pharmaceuticals (Sonoma Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
5445 Conestoga Court, Suite 150, Boulder, CO, USA, 80301
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, and other countries.
Executives
Chad Norman White officer: Interim CFO 645 MOLLY LANE, SUITE 150, WOODSTOCK GA 30189
Jerome J Dvonch officer: Chief Financial Officer 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Robert Grant Edwards officer: Chief Financial Officer 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Poggetto John Dal officer: Chief Financial Officer 1129 N. MCDOWELL BLVD, PETALUMA CA 94954
Amy Moss Trombly officer: Interim CEO 1314 MAIN STREET, SUITE 102, LOUSIVILLE CO 80027
Frederick J Sandford director, officer: CEO and Interim CFO C/O SONOMA PHARMACEUTICALS, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Philippe Weigerstorfer director 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Robert E Miller officer: Chief Financial Officer 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
James J Schutz director, officer: Chief Operating Officer 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Marc Umscheid officer: Chief Strategy/Mkt Officer OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Robert Allen Northey officer: Exec. VP of Res & Devlpment C/O OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Sharon Surrey Barbari director 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Russell Joseph Harrison director OCULUS INNOVATIVE SCIENCES, INC., 1129 NORTH MCDOWELL BLVD., PETALUMA CA 94954
John Mclaughlin director OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Sameer Harish other: Officer of Subsidiary (1) RUTHIGEN, INC., 1129 N. MCDOWELL BLVD, PETALUMA CA 94954

Sonoma Pharmaceuticals (Sonoma Pharmaceuticals) Headlines

From GuruFocus